These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22205194)

  • 21. Controlled-release opioids cause harm and should be avoided in management of postoperative pain in opioid naïve patients.
    Levy N; Mills P
    Br J Anaesth; 2019 Jun; 122(6):e86-e90. PubMed ID: 30915981
    [No Abstract]   [Full Text] [Related]  

  • 22. A randomized, double-blind, placebo-controlled, cross-over pilot study to assess the effects of long-term opioid drug consumption and subsequent abstinence in chronic noncancer pain patients receiving controlled-release morphine.
    Cowan DT; Wilson-Barnett J; Griffiths P; Vaughan DJ; Gondhia A; Allan LG
    Pain Med; 2005; 6(2):113-21. PubMed ID: 15773875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of OROS hydromorphone in the management of cancer pain.
    Gardner-Nix J; Mercadante S
    Pain Pract; 2010; 10(1):72-7. PubMed ID: 19863749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcomes during opioid titration following initiation with or conversion to Remoxy®, an extended-release formulation of oxycodone.
    Roland CL; Setnik B; Cleveland JM; Brown DA
    Postgrad Med; 2011 Jul; 123(4):148-59. PubMed ID: 21680999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of newer opioids in geriatric anesthesia.
    Shafer SL
    Acta Anaesthesiol Belg; 1998; 49(2):91-103. PubMed ID: 9675378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Delayed action and rapidly effective in combination. Hydromorphone--already a WHO stage 3 drug].
    MMW Fortschr Med; 2006 May; 148(19):47. PubMed ID: 16736708
    [No Abstract]   [Full Text] [Related]  

  • 27. Advancement of opioid analgesia with controlled-release oxycodone.
    Levy MH
    Eur J Pain; 2001; 5 Suppl A():113-6. PubMed ID: 11798230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opioid analgesic drugs in the elderly.
    Forman WB
    Clin Geriatr Med; 1996 Aug; 12(3):489-500. PubMed ID: 8853941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of postoperative pain with peridural administration of opioids].
    Chrubasik S; Chrubasik J
    Anaesthesiol Reanim; 1995; 20(1):16-25. PubMed ID: 8526956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
    Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
    Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opioid analgesics: does potency matter?
    Passik SD; Webster L
    J Opioid Manag; 2014; 10(4):263-75. PubMed ID: 25162606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydrocodone extended-release: pharmacodynamics, pharmacokinetics and behavioral pharmacology of a controversy.
    Gould HJ; Paul D
    Pharmacol Res; 2015 Jan; 91():99-103. PubMed ID: 25301538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. KADIAN (morphine sulfate extended-release) capsules for treatment of chronic, moderate-to-severe, nonmalignant pain.
    Ross EL; Hahn K
    Int J Clin Pract; 2008 Mar; 62(3):471-9. PubMed ID: 18261077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone.
    Schoedel KA; McMorn S; Chakraborty B; Zerbe K; Sellers EM
    Pain Physician; 2010; 13(6):561-73. PubMed ID: 21102969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: two randomized controlled trials.
    Grosset AB; Roberts MS; Woodson ME; Shi M; Swanton RE; Reder RF; Buckley BJ
    J Pain Symptom Manage; 2005 Jun; 29(6):584-94. PubMed ID: 15963867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opioid switching and rotation in primary care: implementation and clinical utility.
    Slatkin NE
    Curr Med Res Opin; 2009 Sep; 25(9):2133-50. PubMed ID: 19601703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Normal-release oral morphine starting dose in cancer patients with pain.
    Ripamonti CI; Campa T; Fagnoni E; Brunelli C; Luzzani M; Maltoni M; De Conno F;
    Clin J Pain; 2009 Jun; 25(5):386-90. PubMed ID: 19454871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone.
    Fishman M
    Addiction; 2008 Aug; 103(8):1399-401. PubMed ID: 18855831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
    Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
    Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDA to tighten labeling on long acting opioids.
    McCarthy M
    BMJ; 2013 Sep; 347():f5581. PubMed ID: 24030791
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.